RxDoctor Payments Data

John Kobert, DO

Nephrology · Floresville, TXNPI 1376528810

Payments from drug & device makers

$8,276in general payments, 2019–2025

Across 133 payments — averaging $62.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Travere Therapeutics, Inc.$362
  • OPKO Pharmaceuticals, LLC$230
  • Vifor Pharma, Inc.$213
  • Novartis$159
  • Otsuka America Pharmaceutical, Inc.$144
  • plus $835 from 13 others

What the payments were for

  • Consulting fees$4,69857%
  • Travel & lodging$89011%
  • Food & beverage$2,63732%
  • Education$511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,276 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$267,905
Medicare patients
529
Services billed
2,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol193$122,690
JardianceEmpagliflozin145$104,588
RayaldeeCalcifediol32$37,518
VelphoroSucroferric Oxyhydroxide15$36,818
Sevelamer Carbonate127$35,079
VeltassaPatiromer Calcium Sorbitex34$23,689
LokelmaSodium Zirconium Cyclosilicate50$16,215
Cinacalcet Hcl11$8,755
KerendiaFinerenone12$7,958
Chlorthalidone447$3,804
Calcium Acetate38$3,241
Terazosin Hcl126$2,136
Losartan Potassium321$1,922
Nifedipine ErNifedipine186$1,802
Furosemide434$1,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$6,334$138,905243 claims
Boehringer IngelheimJardiance$120$104,588145 claims
OPKO Pharmaceuticals, LLCRayaldee$230$37,51832 claims
BayerKerendia$104$7,95812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Floresville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →